Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by MrMugsyon Oct 04, 2023 7:54am
158 Views
Post# 35668462

October is a busy month ...

October is a busy month ...Good or Bad ... October is a busy month.

It would be nice if we can get a positive ruling - followed by the start of PK/PD and then followed by a new molecule introduction.

That would pretty much get us where we'd like to be as PK/PD comes to an end and sets us up for P2.

------------------

Predicting the market's move never works so I'll just let Mother Nature deal with that.

Development progress is what I care about ...
1. pills are done and quality checked - that means the process is ready.
2. secondary location for pill manufacture being considered.
3. new formula means faster onset (and faster offset?) - looking for better control in regimen design (opening the door to chronic - round 2 ???)
4. reduced dosing - how low can we actually go?  I don't really care about that for acute as it's in the body for such a short duration ... but I'd like to know what it means for chronic and chronic regimen design.

-----------------

This October is a little different - but still scary like a good halloween horror movie.  Hahaha !


<< Previous
Bullboard Posts
Next >>